Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Gαs protein expression is an independent predictor of recurrence in prostate cancer.

Wang L, Jin G, He C, Guo X, Zhou X, Li M, Ying X, Wang L, Wu H, Zhu Q.

J Immunol Res. 2014;2014:301376. doi: 10.1155/2014/301376. Epub 2014 Mar 31.

2.

Differential expression of the mismatch repair gene hMSH2 in malignant prostate tissue is associated with cancer recurrence.

Velasco A, Hewitt SM, Albert PS, Hossein M, Rosenberg H, Martinez C, Sagalowsky AI, McConnell JD, Marston W, Leach FS.

Cancer. 2002 Feb 1;94(3):690-9. Erratum in: Cancer 2002 May 15;94(10):2800.

4.

Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.

Kupelian PA, Katcher J, Levin HS, Klein EA.

Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1043-52.

PMID:
9169811
5.

Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.

Capitanio U, Scattoni V, Freschi M, Briganti A, Salonia A, Gallina A, Colombo R, Karakiewicz PI, Rigatti P, Montorsi F.

Eur Urol. 2008 Jul;54(1):118-25. doi: 10.1016/j.eururo.2008.02.018. Epub 2008 Feb 26.

PMID:
18314255
6.

Preoperative predictors of pathologic stage T2a and pathologic Gleason score ≤ 6 in men with clinical low-risk prostate cancer treated with radical prostatectomy: reference for active surveillance.

Fu Q, Moul JW, Bañez L, Sun L, Mouraviev V, Xie D, Polascik TJ.

Med Oncol. 2013 Mar;30(1):326. doi: 10.1007/s12032-012-0326-5. Epub 2012 Dec 22.

PMID:
23263824
7.

Presence of high grade tertiary Gleason pattern upgrades the Gleason sum score and is inversely associated with biochemical recurrence-free survival.

Turker P, Bas E, Bozkurt S, Günlüsoy B, Sezgin A, Postacı H, Turkeri L.

Urol Oncol. 2013 Jan;31(1):93-8. doi: 10.1016/j.urolonc.2010.10.009. Epub 2011 Feb 12.

PMID:
21316989
8.

MicroRNA-30c serves as an independent biochemical recurrence predictor and potential tumor suppressor for prostate cancer.

Ling XH, Han ZD, Xia D, He HC, Jiang FN, Lin ZY, Fu X, Deng YH, Dai QS, Cai C, Chen JH, Liang YX, Zhong WD, Wu CL.

Mol Biol Rep. 2014 May;41(5):2779-88. doi: 10.1007/s11033-014-3132-7. Epub 2014 Jan 23.

PMID:
24452717
9.

Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.

Ploussard G, Agamy MA, Alenda O, Allory Y, Mouracade P, Vordos D, Hoznek A, Abbou CC, de la Taille A, Salomon L.

BJU Int. 2011 Jun;107(11):1748-54. doi: 10.1111/j.1464-410X.2010.09728.x. Epub 2010 Sep 30.

10.

[Expression of PIM-1 in prostate cancer tissue and its relationship with PSA recurrence].

Zhang CT, Xu Y, Luo F, Zhang ZH, Liu RL, Yang K, Ma BJ.

Zhonghua Nan Ke Xue. 2012 Apr;18(4):323-6. Chinese.

PMID:
22574367
11.

Prognostic value of insulin-like growth factor II mRNA binding protein 3 in patients treated with radical prostatectomy.

Chromecki TF, Cha EK, Pummer K, Scherr DS, Tewari AK, Sun M, Fajkovic H, Roehrborn CG, Ashfaq R, Karakiewicz PI, Shariat SF.

BJU Int. 2012 Jul;110(1):63-8. doi: 10.1111/j.1464-410X.2011.10703.x. Epub 2011 Nov 11.

12.
13.
14.

Early prostate-specific antigen relapse after radical retropubic prostatectomy: prediction on the basis of preoperative and postoperative tumor characteristics.

Graefen M, Noldus J, Pichlmeier U, Haese A, Hammerer P, Fernandez S, Conrad S, Henke R, Huland E, Huland H.

Eur Urol. 1999;36(1):21-30.

PMID:
10364651
15.

Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence.

Karam JA, Lotan Y, Roehrborn CG, Ashfaq R, Karakiewicz PI, Shariat SF.

Prostate. 2007 May 1;67(6):614-22.

PMID:
17299799
16.

Enhanced expression of centromere protein F predicts clinical progression and prognosis in patients with prostate cancer.

Zhuo YJ, Xi M, Wan YP, Hua W, Liu YL, Wan S, Zhou YL, Luo HW, Wu SL, Zhong WD, Wu CL.

Int J Mol Med. 2015 Apr;35(4):966-72. doi: 10.3892/ijmm.2015.2086. Epub 2015 Jan 30.

PMID:
25647485
17.

Role of microvessel density in predicting recurrence in pathologic Stage T3 prostatic adenocarcinoma.

Gettman MT, Pacelli A, Slezak J, Bergstralh EJ, Blute M, Zincke H, Bostwick DG.

Urology. 1999 Sep;54(3):479-85.

PMID:
10475358
19.

Prognostication of prostate cancer based on NUCB2 protein assessment: NUCB2 in prostate cancer.

Zhang H, Qi C, Wang A, Yao B, Li L, Wang Y, Xu Y.

J Exp Clin Cancer Res. 2013 Oct 16;32:77. doi: 10.1186/1756-9966-32-77.

Supplemental Content

Support Center